An invasive, highly aggressive form of breast cancer. TNBC cells do not contain receptors for estrogen, progesterone, or HER2 and cannot be treated with hormone therapies or medications that work by blocking HER2. Approximately 20 percent of all breast cancers are triple-negative.
Recent Posts
- Profiles in Chemoprotection, Part I
- Our recent autism biomarkers paper selected for Open Access
- Sulforaphane and Epilepsy
- New Study from Korea: Sulforaphane Has Positive Effects in a Mouse Model of Alzheimer’s Disease
- New study indicates ability of oral sulforaphane to boost antioxidant response in the human brain
- Autism, Broccoli, & Urine!
- Exciting News for the Spring
- New Paper on Long Term Use of Broccoli Sprout Supplements and Autism Symptoms
- Dr. Fahey talks about Moringa oleifera in a new podcast
- More Public Interest in Sulforaphane
- Dr. Fahey Talks about Sulforaphane on a New Podcast
- New Reata Scholar Joins the Chemoprotection Center
- The Bioavailability of Nutritional Supplements Rich in Sulforaphane
- Release of new Webinar and Podcast on Isothiocyanates, Nrf2, Moringa & Sulforaphane Supplementation
- An update on links between obesity and cancer
- The Cullman Center Weighs in on Moringa Leaf Protein
- Is the vitamin and phytochemical content of fruit declining?
- Moringa health and economic benefits
- A Matter of Taste
- . . . wheatgrass is not a superfood
- New Coffee Claims Health Benefits of Broccoli
- Will Progeria respond to phytochemicals like sulforaphane?
- Autism Study Frequently Asked Questions
- A Promising New Treatment for Autism Syndrome Disorder (ASD)
- Press Coverage on China Study